Donald A Berry, Ph.D.
Department of Biostatistics, Division of Division of Discovery Science
Present Title & Affiliation
Primary Appointment
Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Adjunct Professor, Department of Statistics, Rice University, Houston, TX
Education & Training
Degree-Granting Education
| 1971 | Yale University, New Haven, CT, USA, PHD, Statistics |
| 1967 | Yale University, New Haven, CT, USA, MA, Statistics |
| 1965 | Dartmouth College, Hanover, NH, USA, AB, Mathematics |
Experience & Service
Academic Appointments
Head, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2010
Professor, Department of Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX, 2000 - Present
Chair, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2010
Endowed Positions
Frank T. McGraw Memorial Chair of Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2010
Selected Publications
Peer-Reviewed Articles
- Park JW, Liu MC, Yee D, Yau C, van ‘t Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Hesten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, for the I-SPY 2 Investigators*. Adaptive Randomization of Neratinib in Early Breast Cancer. New England Journal of Medicine 375(1):11-22, 2016.
- Rugo HS, Olopade OI, DeMichele A, Yau C, van ‘t Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, for the I-SPY 2 Investigators*. Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer. New England Journal of Medicine 375(1):23-34, 2016.
- Berry DA. Bayesian approaches for comparative effectiveness research. Clin Trials 9(1):37-47, 2012. e-Pub 2011. PMID: 21878446.
- Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M, Stadtmauer EA, Biron P, Crown JP, Schmid P, Lotz JP, Rosti G, Bregni M, Demirer T. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol 29(24):3224-31, 2011. e-Pub 2011. PMID: 21768454.
- Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 29(24):3214-23, 2011. e-Pub 2011. PMID: 21768471.
- Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101(23):1642-9, 2009. e-Pub 2009. PMID: 19903805.
- Biswas S, Liu DD, Lee JJ, Berry DA. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials 6(3):205-16, 2009. PMID: 19528130.
- Berry DA, Zhou S, Radich J. Minimal Residual Disease in Acute Lymphoblastic Leukemia (ALL): A literature-based meta-analysis.
Editorials
- Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 9(4):199-207, 2012. PMID: 22064459.
Grant & Contract Support
| Title: | Cancer Center Support Grant (CCSG) - Biostatistics Resource Group (BRG) |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| Title: | Comparative Modeling: Informing Breast Cancer Control Practice and Policy |
| Funding Source: | NIH/NCI subaward via Georgetown University Medical Center |
| Role: | Co-Principal Investigator |
| Title: | I-SPY 2+: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment in the setting of non-response: CORE 02 - STATISTICS AND BIOINFORMATICS |
| Funding Source: | University of California - San Francisco |
| Role: | Core Leader |
| Title: | HRMM Moon Shot - Flagship 1 |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Collaborator |
Patient Reviews
CV information above last modified March 19, 2024